Synthesis of 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives with potential anti-HIV activity

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 2, 2012, Pages 57-65

  Isono, Yohei ^a   Sakakibara, Norikazu ^a   Ordonez, Paula ^b   Hamasaki, Takayuki ^b   Baba, Masanori ^b   Ikejiri, Masahiro ^c   Maruyama, Tokumi ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c OSAKA OHTANI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (3,5 DIMETHYLBENZYL) 5 FLUOROURACIL; 1 BENZYL 3 (3,5 DIMETHYLBENZYL) 6 METHOXYURACIL; 1 BENZYL 3 (3,5 DIMETHYLBENZYL) 6 THIOMETHOXYURACIL; 1 BENZYL 6 CYANO 3 (3,5 DIMETHYLBENZYL) URACIL; 1 CYANOMETHYL 3 (3,5 DIMETHYLBENZYL) 5 FLUOROURACIL; 3 (3,5 DIMETHYLBENZYL) 1 (2 PICOLYL) 5 FLUOROURACIL; 3 (3,5 DIMETHYLBENZYL) 1 (4 PICOLYL) 5 FLUOROURACIL; 5 CHLORO 5,6 DIHYDRO 5 FLUORO 6 METHOXYURACIL; 6 AMINO 1 BENZYL 3 (3,5 DIMETHYLBENZYL) URACIL; 6 AZIDO 1 BENZYL 3 (3,5 DIMETHYLBENZYL) URACIL; 6 CHLORO 1 BENZYL 3 (3,5 DIMETHYLBENZYL) URACIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUNCTIONAL GROUP; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; 3 (3,5 DIMETHYLBENZYL)URACIL; 3-(3,5-DIMETHYLBENZYL)URACIL; DRUG DERIVATIVE; URACIL;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; METHODOLOGY; SYNTHESIS; TUMOR CELL LINE;

ANTI-HIV AGENTS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; HYDROGEN BONDING; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL;

EID: 84858965111     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1844     Document Type: Article

References (21)

1. De Clercq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002; 1:13-25.
2. De Clercq E. New Approaches toward anti-HIV Chemotherapy. J Med Chem 2005; 48:1297-1313.
3. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007; 6:1001-1018.
4. Baba M, Tanaka H, De Clercq E, et al. Highly specifc inhibition of human immunodefciency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun 1989; 165:1375-1381.
5. Buckheit RW, Jr., Watson K, Fliakas-Boltz V, et al. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodefciency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother 2001; 45:393-400
6. Maruyama T, Kozai S, Yamasaki T, et al. Synthesis and antiviral activity of 1,3-disubstituted uracils against HIV-1 and HCMV. Antivir Chem Chemother 2003; 14:271-279.
7. Maruyama T, Kozai S, Demizu Y, et al. Synthesis and anti-HIV-1 and anti-HCMV activity of 1-substituted 3-(3,5-dimethylbenzyl) uracil derivatives. Chem Pharm Bull (Tokyo) 2006; 54:325-333.
8. Maruyama T, Ikejiri M, Izawa K, Onishi T. Synthesis and biological activity of fuorinated nucleosides. In Ojima I (Editor). Fluorine in Medicinal Chemistry and Chemical Biology. Chichester: John Wiley & Sons 2009; pp165-198.
9. Cresswell RM, Wood HCS. The biosynthesis of pteridines. I. The synthesis of ribofavine. J Chem Soc 1960; 4768-4775.
10. Ishikawa I, Itoh T, Melik-Ohanjanian RG, et al. Synthesis and X-Ray Analysis of 1-Benzyl-6-chlorouracil. Heterocycles 1990; 31:1641-1646.
11. Mitsunobu O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981; 1:1-28.
12. Gogoi M, Sandhu JS, Baruah JN. Phase-transfer catalyzed preparation of 6-alkoxy and 6-thioalkoxy-1,3-dimethyluracils. Indian Journal of Chemistry, Section B 1984; 23B:851-852.
13. Ohkura K, Uchiyama S, Aizawa K, Nishijima K, Seki K. Photochemical synthesis of naphthocyclobutapyrimidines via 1,2-cycloaddition of 6-chloro-1,3-dimethyluracil with naphthalenes. Heterocycles 2002; 57:1403-1408.
14. Nagata W, Yoshioka M. Organic Reactions. Vol. 25. New York: John Wiley & Sons, Inc. 1977; pp. 255-476.
15. Bhuyan PJ, Borah HN, Sandhu JS. Studies on uracils: an efficient method for the synthesis of novel 1-allyl-6-(1,2,3-triazolyl) analogs of HEPT. Journal of the Chemical Society, Perkin Transactions 1 1999; 21:3083-3084.
16. Hirota K, Maruhashi K, Asao T, Senda S. Pyrimidine derivatives and related compounds. XLIV. Thermolysis of 6-azido-1,3-dimethyluracil to a pyrimido [5,4-g] pteridine derivative. Chem Pharm Bull (Tokyo) 1982; 30:3377-3379.
17. Baker BR, Jackson GDF. Nonclassical antimetabolites XXIV. Alkylation of 5-fuorouracil. J Pharm Sci 1965; 54:1758-1762.
18. Kozai S, Fukagawa T, Maruyama T. A new method for the synthesis of N3-alkylated analogs of 5-fuorouracil. Journal of the Chemical Society, Perkin Transactions 1 1998; 19:3145-3146.
19. Baba M, De Clercq E, Tanaka H, et al. Potent and selective inhibition of human immunodefficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 1991; 88:2356-2360.
20. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20:309-321.
21. De Clercq E, Descamps J, Verhelst G, et al. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis 1980; 141:563-574.